Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 12/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616803 | 0.90 | RIPK2 (0.43) | RIPK2PTGER4HPGDCASRKDM4E | |
| SCHEMBL2553689 | 0.87 | PTGER4 (0.36) | PTGER4HPGDCASRKDM4ERECQL | |
| SCHEMBL14616790 | 0.84 | RIPK2 (0.43) | RIPK2PTGER4HPGDCASRKDM4E | |
| SCHEMBL14616801 | 0.83 | RIPK2 (0.49) | RIPK2PTGER4HPGDCASRKDM4E | |
| SCHEMBL14616806 | 0.80 | RIPK2 (0.39) | RIPK2PTGER4CASRHSD17B10ALDH1A1 | |
| SCHEMBL14616793 | 0.80 | RIPK2 (0.44) | RIPK2PTGER4HPGDCASRKDM4E | |
| SCHEMBL14616812 | 0.78 | RIPK2 (0.41) | RIPK2PTGER4CASR | |
| SCHEMBL14616813 | 0.78 | RIPK2 (0.41) | RIPK2PTGER4CASRKDM4EALDH1A1 | |
| SCHEMBL14642705 | 0.78 | RIPK2 (0.51) | RIPK2PTGER4HPGDKDM4ERECQL | |
| SCHEMBL14616825 | 0.78 | RIPK2 (0.40) | RIPK2HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018039-A1 | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K3 | RIPK2 255/4885PTGER4 3190/4885HPGD 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.